Lifeboat Foundation

Artemis I will be the first in a series of increasingly complex missions to build a sustained human presence at the Moon for decades to come.

Deep Learning AI Specialization: https://imp.i384100.net/GET-STARTED
ChatGPT from Open AI has shocked many users as it is able to complete programming tasks from natural language descriptions, create legal contracts, automate tasks, translate languages, write articles, answer questions, make video games, carry out customer service tasks, and much more — all at the level of human intelligence with 99% percent of its outputs. PAL Robotics has taught its humanoid AI robots to use objects in the environment to avoid falling when losing balance.

AI News Timestamps:
0:00 Why OpenAI’s ChatGPT Has People Panicking.
3:29 New Humanoid AI Robots Technology.
8:20 Coursera Deep Learning AI

Continue reading “Why OpenAI’s New ChatGPT Has People Panicking | New Humanoid AI Robots Technology” »

Lex Fridman Podcast full episode: https://www.youtube.com/watch?v=2oHH4aClJQs.
Please support this podcast by checking out our sponsors:
- True Classic Tees: https://trueclassictees.com/lex and use code LEX to get 25% off.
- Audible: https://audible.com/lex to get 30-day free trial.
- InsideTracker: https://insidetracker.com/lex to get 20% off.
- ExpressVPN: https://expressvpn.com/lexpod to get 3 months free.

GUEST BIO:
Noam Brown is a research scientist at FAIR, Meta AI, co-creator of AI that achieved superhuman level performance in games of No-Limit Texas Hold’em and Diplomacy.

Continue reading “AI that learns to negotiate with humans” »

We evaluate davinci-003 across a range of classification, summarization, and generation tasks. Using Scale Spellbook, the platform for large language model apps, we show where davinci-003 significantly outperforms the prior version and where it still has room to improve.

Character is a full stack Artificial General Intelligence (AGI) company.

What if you could create your own AI, and it was always available to help you with anything?

Imagine everything it could do for you, from being your own personal teacher, assistant or even friend. Two months after launching in September, our beta generates 1 billion words per day. Get a glimpse of the future at character.ai.

Tune in at 9:00 a.m. PT / 12:00 p.m. ET on Wed. October 12 when Microsoft CEO Satya Nadella kicks off the comnpany’s Ignite conference.

Never miss a deal again! See CNET’s browser extension 👉 https://bit.ly/39Ub3bv.

Biotech startup Lucy Therapeutics is developing mitochondrial-based small molecule therapies for neurological diseases and recently revealed the first two drugs to emerge from its lead programme targeting Parkinson’s. The company, which takes its name from the 3.2-million-year-old fossil of an ancestor of humankind, presented “promising preclinical data” at the Michael J Fox Foundation’s Parkinson’s Disease Therapeutics Conference in October.

The data shown by Lucy Therapeutics demonstrated that its compounds were able to reverse mitochondrial dysfunctions linked to Parkinson’s. In cellular models of the disease, the drugs boosted levels of cellular energy molecule ATP, prevented the death of neurons, and reduced levels of other hallmarks of Parkinson’s, including a-synuclein.

Longevity. Technology: Mitochondria are widely known as the ‘power generators’ within our cells, and their dysfunction has been linked to a range of age-related diseases. But the role of mitochondria extends beyond cellular energy as they also dictate many of a cell’s key functions. Lucy Therapeutics was founded on the hypothesis that diseases with rate-limiting steps involving mitochondrial dysfunction can potentially be treated by modulating key mitochondrial protein targets. To find out more, we caught up with the company’s founder and CEO, Dr Amy Ripka.

This eye implant engineered from proteins in pig skin can restore sight in people with impaired eyesight as well as the blind.

Biological supramolecular assemblies, such as phospholipid bilayer membranes, have been used to demonstrate signal processing via short-term synaptic plasticity (STP) in the form of paired pulse facilitation and depression, emulating the brain’s efficiency and flexible cognitive capabilities. However, STP memory in lipid bilayers is volatile and cannot be stored or accessed over relevant periods of time, a key requirement for learning. Using droplet interface bilayers (DIBs) composed of lipids, water and hexadecane, and an electrical stimulation training protocol featuring repetitive sinusoidal voltage cycling, we show that DIBs displaying memcapacitive properties can also exhibit persistent synaptic plasticity in the form of long-term potentiation (LTP) associated with capacitive energy storage in the phospholipid bilayer. The time scales for the physical changes associated with the LTP range between minutes and hours, and are substantially longer than previous STP studies, where stored energy dissipated after only a few seconds. STP behavior is the result of reversible changes in bilayer area and thickness. On the other hand, LTP is the result of additional molecular and structural changes to the zwitterionic lipid headgroups and the dielectric properties of the lipid bilayer that result from the buildup of an increasingly asymmetric charge distribution at the bilayer interfaces.